Literature DB >> 26795367

Tetraspanins displayed in retrovirus-derived virus-like particles and their immunogenicity.

H R Soares1, R Castro1, H A Tomás1, A F Rodrigues1, P Gomes-Alves1, B Bellier2, D Klatzmann2, M J T Carrondo3, P M Alves1, A S Coroadinha4.   

Abstract

Virus-like particles (VLPs) are a particular subset of subunit vaccines which are currently explored as safer alternatives to live attenuated or inactivated vaccines. VLPs derived from retrovirus (retroVLPs) are commonly used as scaffolds for vaccine candidates due to their ability to incorporate heterologous envelope proteins. Pseudotyping retroVLPs is however not a selective process therefore, host cellular proteins such as tetraspanins are also included in the membrane. The contribution of these host-proteins to retrovirus immunogenicity remains unclear. In this work, human cells silenced and not silenced for tetraspanin CD81 were used to produce CD81(-) or CD81(+) retroVLPs. We first analyzed mice immune response against human CD81. Despite effective silencing of CD81 in retroVLP producing cells, both humoral and cellular immune responses showed persistent anti-CD81 immunogenicity, suggesting cross reactivity to related antigens. We thus compared the incorporation of related tetraspanins in retroVLPs and showed that decreased CD81 incorporation in CD81(-) retro-VLPs is compensated by an increased incorporation of CD9 and CD63 tetraspanins. These results highlight the dynamic nature of host-derived proteins incorporation in retroVLPs membrane, which should be considered when retrovirus-based biopharmaceuticals are produced in xenogeneic cells.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD63; CD81; CD9; Immunogenicity; RetroVLPs; Retrovirus; Tetraspanins; Vaccines; Viral vectors; Virus-like particles

Mesh:

Substances:

Year:  2016        PMID: 26795367     DOI: 10.1016/j.vaccine.2015.12.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.

Authors:  Fabien Pitoiset; Thomas Vazquez; Beatrice Levacher; Djamel Nehar-Belaid; Nicolas Dérian; James Vigneron; David Klatzmann; Bertrand Bellier
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

2.  Biochemical and proteomic characterization of retrovirus Gag based microparticles carrying melanoma antigens.

Authors:  Reet Kurg; Olavi Reinsalu; Sergei Jagur; Kadri Õunap; Liisi Võsa; Sergo Kasvandik; Kärt Padari; Kiira Gildemann; Mart Ustav
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

3.  Flexible pseudotyping of retrovirus using recombinase-mediated cassette exchange.

Authors:  Hugo R Soares; Ana I Almeida; Hélio A Tomás; Paula M Alves; Ana S Coroadinha
Journal:  Biotechnol Lett       Date:  2018-01-20       Impact factor: 2.461

4.  Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81.

Authors:  Hugo R Soares; Rute Castro; Hélio A Tomás; Manuel J T Carrondo; Paula M Alves; Ana S Coroadinha
Journal:  AMB Express       Date:  2019-02-07       Impact factor: 3.298

Review 5.  All the small things: How virus-like particles and liposomes modulate allergic immune responses.

Authors:  Bernhard Kratzer; Sandra Hofer; Maja Zabel; Winfried F Pickl
Journal:  Eur J Immunol       Date:  2019-12-15       Impact factor: 5.532

6.  Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus.

Authors:  Diego Fontana; Ernesto Garay; Laura Cervera; Ricardo Kratje; Claudio Prieto; Francesc Gòdia
Journal:  Vaccines (Basel)       Date:  2021-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.